stoxline Quote Chart Rank Option Currency Glossary
Seelos Therapeutics, Inc. (SEEL)
0.5235  -0.011 (-1.98%)    07-18 16:00
Open: 0.53
High: 0.5523
Volume: 274,265
Pre. Close: 0.5341
Low: 0.511
Market Cap: 1(M)
Technical analysis
2024-07-18 4:54:23 PM
Short term     
Mid term     
Targets 6-month :  0.96 1-year :  1.22
Resists First :  0.82 Second :  1.04
Pivot price 0.58
Supports First :  0.47 Second :  0.39
MAs MA(5) :  0.54 MA(20) :  0.6
MA(100) :  3.17 MA(250) :  61.12
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  12.6 D(3) :  13.4
RSI RSI(14): 31.4
52-week High :  398.39 Low :  0.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SEEL ] has closed above bottom band by 24.1%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 73 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.55 - 0.56 0.56 - 0.56
Low: 0.5 - 0.51 0.51 - 0.51
Close: 0.52 - 0.52 0.52 - 0.53
Company Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Headline News

Fri, 17 May 2024
Struggling Seelos raises $1.1M after string of clinical setbacks - Green Market Report

Thu, 16 May 2024
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PR Newswire

Tue, 14 May 2024
Seelos Therapeutics Announces Common Stock Reverse Split - TipRanks

Tue, 14 May 2024
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - StockTitan

Tue, 14 May 2024
Seelos Therapeutics enacts 1-for-8 reverse stock split -

Tue, 14 May 2024
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.15e+006 (%)
Held by Institutions 1.2 (%)
Shares Short 98 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 45.7 %
Return on Equity (ttm) -172.6 %
Qtrly Rev. Growth 1.97e+006 %
Gross Profit (p.s.) -14.98
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -34.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.06
Stock Dividends
Dividend 0
Forward Dividend 215570
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android